Clinical Trial Update: Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating vorinostat (MK-0683) with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2020-11-18